Actuate Therapeutics
web2Actuate Therapeutics is a clinical-stage biopharmaceutical company developing experimental canc...
About
Actuate Therapeutics is a clinical-stage biopharmaceutical company developing experimental cancer treatments that inhibit glycogen synthase kinase-3, an enzyme involved in cell signaling and tumor growth. Its main drug candidate, elraglusib, is being studied for difficult-to-treat cancers and is intended to affect tumor survival pathways and immune responses. The company has tested an intravenous formulation in early and mid-stage clinical studies, including research involving pancreatic cancer and pediatric solid tumors. It is also developing an oral tablet formulation for further clinical evaluation. Actuate licenses the underlying compound from university research institutions and has not established commercial sales of an approved medicine.
Explore this sector
Exchange listings
Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.
Actuate Therapeutics profile.
Expert coverage
No published expert evaluations are available for this project yet.
Orbitrum Academy